Docteur ELODIE BAUER

Bibliographie

• Vêtements féminins de luxe en images dans les rites religieux et les processions de l’Athènes classique

  2023

  ArticleMètis. Anthropologie des mondes grecs anciens

• New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case–control MISSIL study

  2022

  ArticleRheumatology

• B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics

  2021

  ArticleAnnals of the Rheumatic Diseases

• Relationship between calcifications and structural lesions on hand radiography and axial calcifications on CT-scan

  2020

  ArticleMedicine

• Study of vertebral fracture and Scanographic Bone Attenuation Coefficient in rheumatoid arthritis and ankylosing spondylitis vs. controls

  2019

  ArticleScientific Reports

• Vertebral fracture prevalence and measurement of the scanographic bone attenuation coefficient on CT-scan in patients with systemic sclerosis

  2018

  ArticleRheumatology International

• Febrile low back pain: Consider septic interspinous bursitis

  2016

  ArticleJoint Bone Spine

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

• CHRU NANCY - HOPITAUX DE BRABOIS

  Rue DU MORVAN, 54511 Vandoeuvre-lès-Nancy

  ☎ 0383153030Hospitalier🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Scleroderma: increased biosynthesis of triple-helical type I and type III procollagens associated with unaltered expression of collagenase by skin fibroblasts in culture

  The Journal of clinical investigation · 1979

  📚 262 citations🎯 RCR 9.77🔓 Open Access📄 PDF gratuit ↗
• 2

  Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis

  Arthritis and rheumatism · 1995

  📚 105 citations🎯 RCR 3.96Top 11% NIH🩺 Clinique

  Lire l'abstract Crossref ↓

  AbstractObjective.To develop guidelines for therapeutic trials designed to improve the overall course of systemic sclerosis (SSc), that is, to reduce the development of significant organ damage or death.Methods.A committee developed general guidelines for patient inclusion and exclusion criteria, randomization, blinding of patients and physicians, controls, duration of the trial, investigator training, responses, samples size, study dropouts, statistical analyses, data management, and safety monitoring. Delphi and nominal group techniques were used.Results.Briefly, patients with diffuse cutaneous SSc of less than 24 months' duration should be included because they are at greatest risk for the development of severe organ damage and death. Patients should be excluded if they have other connective tissue diseases, SSc‐like illnesses related to exposures or ingestions, severe existing internal organ damage, an unacceptable risk of side effects, or concurrent therapies that might independently influence the outcome. Randomized, double‐blind, placebo‐controlled trials are preferred. The treatment and followup period must be long enough to permit observation of any disease modification, which is likely to require 18–36 months, unless an extraordinarily effective therapy is identified. Responses selected should be quantitative, consistently and accurately reflect activity of SSc in major target organs (not solely the skin), be sensitive to change, and be standardized, with limited variability. An example of a set of responses is given. Surrogate responses are desirable, but none have been validated as correlating with organ damage.Conclusion.Guidelines have been established for trials of disease‐modifying interventions in SSc. These guidelines will need to be altered as additional information becomes available. Any given protocol will be individualized based on the nature of the intervention and objectives of the study. Nonetheless, each study team should develop a protocol that meets the spirit of these guidelines.

• 3

  Arthritis-related B cell epitopes in collagen II are conformation-dependent and sterically privileged in accessible sites of cartilage collagen fibrils

  The Journal of biological chemistry · 1998

  📚 81 citations🎯 RCR 1.79🔓 Open Access📄 PDF gratuit ↗

Publications scientifiques (29) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche